by Cell Reports Medicine
A novel co-targeting design promises to heighten the effects of chimeric antigen receptor (CAR) T-cell activity in certain B-cell lymphoma patients, a population that can benefit from CAR...
by Clinical Cancer Research
Mesothelin-directed chimeric antigen receptor (CAR) T-cells have had only limited success in treating pancreatic ductal adenocarcinoma (PDAC), but researchers have uncovered a strategy to overcome...
by The New England Journal of Medicine
Chimeric antigen receptor (CAR) T-cell therapy could have a future role in managing autoimmune disorders, based on emerging evidence. Researchers suspected ablation of B cells might...
by Blood Advances
Scientists have developed a new model that identifies individuals with relapsed/refractory large B-cell lymphomas (R/R LBCL) who are poor candidates for CD19-targeted chimeric antigen receptor...
by Nature.com
Socioeconomic disparities may narrow access to allogeneic hematopoietic cell transplantation (allo-HCT) among patients with acute myeloid leukemia (AML), but new research suggests these factors...
by ASTCT Talks
In this episode "ASTCT Talks,” hosts Rebecca Epperly, MD, and Aimee Talleur, MD, from St. Jude Children's Research Hospital, dive into the pioneering realm of CAR T-cell therapy and...